SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag)

1/2
Price:
Size:
Number:

SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag): Product Information

Purity
> 90 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag)(10108-H05H) at 2μg/mL (100μL/well) can bind SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag)(40150-V08B1),the EC50 of SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag)(40150-V08B1) is 400-850 ng/mL.
Protein Construction
A DNA sequence encoding the S1 subunit of SARS-CoV (isolate:WH20) spike (AAX16192.1) (Met1-Arg667) was expressed with a C-terminal polyhistidine tag.
Accession#
Expressed Host
Baculovirus-Insect Cells
Species
SARS
Predicted N Terminal
Ser 14
Molecule Mass
The recombinant S1 subunit of SARS-CoV (isolate:WH20) spike comprises 665 amino acids and has a predicted molecular mass of 74.4 kDa. The apparent molecular mass of the protein is approximately 85.8 kDa in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile 20 mM Tris, 500 mM NaCl, 10 % glycerol, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag): Images

Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag)(10108-H05H) at 2μg/mL (100μL/well) can bind SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag)(40150-V08B1),the EC50 of SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag)(40150-V08B1) is 400-850 ng/mL.

Citation List

SARS-CoV Spike/S1 Protein (S1 Subunit, His Tag): Synonyms

coronavirus s1 Protein, SARS; coronavirus s2 Protein, SARS; coronavirus spike Protein, SARS; cov spike Protein, SARS; ncov RBD Protein, SARS; ncov s1 Protein, SARS; ncov s2 Protein, SARS; ncov spike Protein, SARS; novel coronavirus RBD Protein, SARS; novel coronavirus s1 Protein, SARS; novel coronavirus s2 Protein, SARS; novel coronavirus spike Protein, SARS; RBD Protein, SARS; S1 Protein, SARS; s2 Protein, SARS; Spike RBD Protein, SARS

Coronavirus spike Background Information

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
References
  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

2019-nCoV Coronavirus spike Proteins

  • Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
    Author
    De Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
    Author
    Khan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Antibody responses to SARS-CoV-2 in patients with COVID-19
    Author
    Long, QX;Liu, BZ;Deng, HJ;Wu, GC;Deng, K;Chen, YK;
    Year
    2020
    Journal
    Nature Medicine
  • Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals
    Author
    Zhu, Y;Yu, D;Han, Y;Yan, H;Chong, H;Ren, L;Wang, J;
    Year
    2020
    Journal
    bioRxiv
  • Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
    Author
    Chi, X;Liu, X;Wang, C;Zhang, X;Ren, L;Jin, Q;Wang, J;
    Year
    2020
    Journal
    bioRxiv
  • Immunogenicity of a DNA vaccine candidate for COVID-19
    Author
    Smith, TRF;Patel, A;Ramos, S;Elwood, D;Zhu, X;Yan, J;Gary, EN;Walker, SN;Schultheis, K;Purwar, M;Xu, Z;Walters, J;Bhojnagarwala, P;Yang, M;Chokkalingam, N;Pezzoli, P;Parzych, E;Reuschel, EL;Doan, A;Tursi, N;Vasquez, M;Choi, J;Tello-Ruiz, E;Maricic, I;Bah, MA;Wu, Y;Amante, D;Park, DH;Dia, Y;Ali, AR;Zaidi, FI;Generotti, A;Kim, KY;Herring, TA;Reeder, S;Andrade, VM;Buttigieg, K;Zhao, G;Wu, JM;Li, D;Bao, L;Liu, J;Deng, W;Qin, C;Brown, AS;Khoshnejad, M;Wang, N;Chu, J;Wrapp, D;McLellan, JS;Muthumani, K;Wang, B;Carroll, MW;Kim, JJ;Boyer, J;Kulp, DW;Humeau, LMPF;Weiner, DB;Broderick, KE;
    Year
    2020
    Journal
    Nat Commun
  • SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
    Author
    Xie, L;Sun, C;Luo, C;Zhang, Y;Zhang, J;Yang, J;Chen, L;
    Year
    2020
    Journal
    bioRxiv
  • Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
    Author
    Hanson, QM;Wilson, KM;Shen, M;Itkin, Z;Eastman, RT;Shinn, P;Hall, MD;
    Year
    2020
    Journal
    bioRxiv
  • Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals
    Author
    Zhang, J;Qu, X;
    Year
    2020
    Journal
    medRxiv
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.